Novo Nordisk A/S
Procoagulant antibodies
Last updated:
Abstract:
The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.
Status:
Grant
Type:
Utility
Filling date:
29 Jan 2021
Issue date:
11 Jan 2022